Prostate cancer is the second most commonly diagnosed cancer in men. Recent evidence suggests that reduced expression of target protein antigens and human leukocyte antigen (HLA) molecules is the predominant immune escape mechanism of malignant prostate tumor cells. The purpose of this study was to investigate the prospect of antigen specific immunotherapy against prostate cancer via the HLA class II pathway of immune recognition. Here, we show for the first time that prostate cancer cells express HLA class II proteins that are recognized by CD4 þ T cells. Prostate tumor cells transduced with class II molecules efficiently presented tumor-associated antigens/peptides to CD4 þ T cells. This data suggests that malignant prostate tumors can be targeted via the HLA class II pathway, and that class II-positive tumors could be employed for direct antigen presentation, and CD4 þ T-cell mediated tumor immunotherapy.
Introduction
Prostate cancer is the second most commonly diagnosed cancer in men. [1] [2] [3] While surgery, hormones, radiation and chemotherapy remain the treatments of choice for the early stages of prostate cancer, there is no effective treatment for patients who develop recurrences, or for those who have metastatic disease at the time of diagnosis. 1, [4] [5] [6] Each technique, while helpful, is individually invasive and may induce adverse side effects. Regardless of the stage of prostate cancer, current methods of treatment provide only short-term relief from the disease. Thus, immunotherapy may be a more effective option for patients with metastatic prostate tumors as reported previously. [7] [8] [9] [10] The human leukocyte antigen (HLA) system is the focus for most immunotherapeutic strategies because of its crucial function in all adaptive immune responses. [11] [12] [13] [14] HLA class I molecules are constitutively expressed on most nucleated cells in the body. By contrast, class II molecules are typically expressed on professional antigen-presenting cells (APCs) such as B cells, macrophages, dendritic cells and thymic epithelial cells. [13] [14] [15] We and others have shown that some tumors also express class II proteins and the immune components of the HLA class II pathway. [11] [12] [13] [14] [15] In addition, tumor cells can be induced with cytokine interferon-g (IFN-g) to express significant levels of HLA class II proteins. [11] [12] [13] [14] [15] While some tumors express class II molecules, formation and delivery of functional class IIpeptide complexes are a prerequisite for priming CD4 þ T cells in adaptive immune responses.
The immunobiology of prostate malignancy mainly focuses on immunotherapy through the HLA class I pathway of antigen presentation to CD8 þ cytotoxic T cells. [16] [17] [18] While this type of therapy has shown limited success in killing prostate tumor cells, an elevated and sustainable immune response cannot be achieved without stimulation of the immune system via the HLA class II pathway. [19] [20] [21] [22] The HLA class II molecule is an a/b heterodimer that is synthesized and assembled in the endoplasmic reticulum along with a third glycoprotein, the invariant chain (Ii). 23, 24 The associated complex is transported from the endoplasmic reticulum (ER) through the trans-Golgi apparatus to endosomes for further processing. A non-classical class II molecule, HLA-DM, controlled by cofactor HLA-DO, acts to remove CLIP (class II-associated invariant chain peptide) from HLA class II and further facilitate binding of processed antigens from the endosomal/lysosomal compartments. [24] [25] [26] HLA-DM acts as a selective regulator of peptide loading and may also function in establishing patterns of immunodominance and epitope selection. Both exogenous and endogenous antigens including tumor antigens can be processed in the acidic endosomal and lysosomal compartments and delivered by the HLA class II pathway for CD4 þ T-cell recognition. A variety of cathepsins and reductases located within the endocytic compartments of tumor cells can also selectively cleave and process antigens into ligands capable of being presented via the class II pathway. 27, 28 Understanding this pathway of tumor cell antigen presentation and immune recognition is necessary in order to develop new therapeutic strategies for the treatment of prostate cancer.
There are a few candidate tumor associated antigens that have been extensively studied as targets for the immunotherapy of prostate cancer. Prostate-specific antigen, prostatic acid phosphatase and prostate-specific membrane antigen (PSMA) are arguably the best characterized prostate associated tumor antigens, [19] [20] [21] [22] containing both class I-and class II-restricted peptides for T-cell recognition. While class I-restricted cytolytic CD8 þ T cells are the main effector cells in killing tumors, class II-restricted CD4 þ T cells play critical roles in initiating, regulating and maintaining antitumor immune responses. [19] [20] [21] [22] Thus, we examined whether malignant prostate tumors express functional HLA class II molecules. We show that the majority of prostate tumors express detectable levels HLA class II proteins recognizable by CD4 þ T cells. We also show that prostate tumor cells can be genetically manipulated into efficient APCs, capable of stimulating tumor antigenspecific T cells via the class II pathway.
Materials and methods

Cell lines and primary tumors
Prostate cancer cell lines DU145, PC-3, DuPro, LnCap and CWR22Rv1 cells were grown in RPMI medium containing either 10% heat-inactivated bovine growth serum (BGS) (HyClone, Logan, UT, USA), heat-inactivated cosmic calf serum (CCS) (HyClone) or fetal bovine serum (FBS) (HyClone) plus 50 U ml À1 penicillin, 50 mg ml À1 streptomycin (Mediatech Inc, Herndon, VA, USA), and L-glutamine (Mediatech) as a supplement 260 mg ml À1 . Cells were grown in 100 Â 20 mm sterile culture dishes in a fully humidified incubator containing 5% CO 2 at 371 C. In some cases, cells were treated with varying concentrations of IFN-g (Calbiochem, San Diego, CA, USA) for 24-72 h. The B-cell line Frev was grown in complete Iscove's Modified Dulbecco's Medium (IMDM) (Mediatech). The CD4 þ T-cell line A9, which was raised against PSMA 206À220 peptide, was grown in complete RPMI containing 10% FBS, 50 U ml 
Peptides
The human PSMA peptide, PSMA 206À220 (sequence GKVFRGNKVKNAQLA) was produced using Fmoc technology and an Applied Biosystems Synthesizer. 29 Analysis of the peptide was performed using reverse phase highperformance liquid chromatography purification and mass spectrometry, showing a peptide purity of 499%.
Antibodies
The antibody DA6 was used to detect the presence of the alpha (a)-subunit (33 kDa) and XD5 was used to detect the presence of the beta (b)-subunit (25 kDa) of the class II molecules. [30] [31] [32] HLA-DR specific antibody L243 was used to detect the presence of the class II a/b heterodimer.
30-32 Pin 1.1 was used to detect the presence of the Ii (31 kDa) and JSB-DM for HLA-DM molecules. Antibodies were obtained from Dr Janice Blum of Indiana University, Indianapolis. The secondary antibodies used were horseradish peroxidase conjugated goat anti-mouse (Pierce, Rockford, IL, USA), anti-rabbit or anti-goat IgG (Santa Cruz Biotechnologies, CA, USA).
Transfection assays
Prostate cancer cell lines PC-3 and CWR22Rv1 were transduced using retroviral vectors for constitutive expression of HLA-DR4 (DRB1*0401) with linked drug selection markers for hygromycin and histidinol resistance. 33 Expression of surface HLA-DR4 complexes on prostate cancer cells was confirmed by flow cytometric analysis using the DR4-specific monoclonal antibody, 359F10.
33,34 PC-3.DR4 and CWR22Rv1.DR4 cells expressed similar levels of class II proteins on the surface.
Western blot analysis
Prostate cancer cell lines (DU145, PC-3, DuPro, LnCap and CWR22Rv1) as well as malignant primary prostate tissues and matched controls (Table 1) were lysed using prepared lysis buffer (10 mM Trizma base, 150 mM NaCl, 1% Triton-X 100). Lysates containing equal protein concentrations were separated on 4-12% 1.5 mm Bis/ Tris NuPage gels in 2-(N-morpholino)ethenesulfonic acid (MES) buffer (Novex/Invitrogen, Grand Island, NY, USA). Proteins were transferred onto nitrocellulose paper (Pierce) and probed with antibodies for detection of HLA class II molecules and other components of the class II pathway. 35 Blots were incubated with chemiluminescent supersignal (Pierce) and exposed to blue X-ray films (Pierce).
Flow cytometric analysis
Prostate cancer cell lines DU145, LnCap, PC-3, DuPro, CWR22Rv1PC-3.DR4 and a melanoma line J3 were grown in RPMI þ CCS and stained with HLA-DR-specific antibody L243. Retrovirally transduced PC-3.DR4, CWR22Rv1.DR4 and J3.DR4 cells were stained with HLA-DR4-specific antibody (359-F10) followed by secondary antibody labeled with fluorescein isothiocyanate. 34 Samples were analyzed on a FACScan using CellQuest software (BD Bioscience, Mountain View, CA, USA). Background fluorescence was evaluated using irrelevant isotype-matched antibodies (NN4 and IN-1) as described. 31, 34 Melanoma line J3 constitutively express HLA-DR molecules and was used as a control. 33 Antigen presentation assays PC-3 and CWR22Rv1 cells were cultured in complete RPMI þ CCS. Cells were washed and cocultured with human primary CD4 þ T cells in 96-well flat-bottomed Prostate cancer cells and class II AR Younger et al plate for 48 h. 36 Human CD4 þ T cells were obtained from blood samples from DR þ healthy individuals with written consent. The plates were stored in À801 C until tested for IFN-g production. T-cell production of IFN-g was quantitated by enzyme-linked immunosorbent assay (ELISA). 37 HLA-DR4-transfected prostate cancer cell lines PC3.DR4 and CWR22Rv1.DR4 were also cultured in complete RPMI þ CCS and examined for their ability to stimulate class II-restricted peptide specific CD4 þ T cells. To do that, PC3.DR4 cells were incubated with whole PSMA or PSMA 206À220 overnight at 371 C in culture media. Cells were washed and cocultured with the PSMA 206À220 peptide-specific CD4 þ T cells (A9 cells) for 24 h as described. 32, 33 To study endogenous presentation, CWR22Rv1.DR4 cells were cocultured with the A9 cells for 24 h. Production of interleukin-2 was quantitated by ELISA. 38 All assays were repeated at least three times with the s.e. for triplicate samples within a single experiment reported.
Enzyme-linked immunosorbent assay
To analyze cytokines interleukin-2 and IFN-g, supernatants were evaluated by ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. [37] [38] [39] Anti-IFN-g was purchased from R&D Systems, and anti-IL-2 was purchased from SigmaAldrich (St Louis, MO, USA). All assays were repeated at least three times.
Results
Human primary prostate tumors express HLA class II proteins
Professional APCs express high levels of HLA class II proteins but malignant tumors rarely express detectable levels of these molecules allowing them to evade CD4 þ T-cell recognition. Although CD8 þ T cells are main effector cells in the killing of tumors, class II-restricted CD4 þ T cells are essential for the maintenance of CD8 þ T cells and effective killing of tumors. To test whether primary prostate tumors express HLA class II proteins, malignant prostate tissues (n ¼ 20) and matched normal prostate tissue samples (n ¼ 20) were analyzed by western blotting for the detection of HLA-DR molecules. Data showed that 12 out of 20 tumor samples (60%) expressed HLA-DR molecules ( Table 1 ), suggesting that the majority of prostate tumors express class II proteins.
Different culture condition leads to HLA class II protein expression in human prostate cancer cell lines
To examine whether prostate cancer cell lines express functional class II molecules, cells were grown in three different culture conditions. Western blot analysis showed that prostate cancer cell lines PC-3, DuPro, LnCap and CWR22Rv1 grown in RPMI þ BGS expressed HLA-DRa (Figure 1a) . Interestingly, LnCap, PC-3, DuPro and CWR22Rv1 cells grown in RPMI þ BGS or RPMI þ FBS expressed very low to undetectable levels of DRb and no HLA ab dimer (data not shown). DU145 cells grown in all three media failed to express detectable levels of class II molecules even in the presence of IFN-g (Figure 1a ). Furthermore, incubation with IFN-g, which is known to upregulate class II molecules in different cell types, induced higher levels of class II DRa protein in some prostate tumor cell lines (Figure 1a) . Surprisingly, we found that prostate cancer cell lines (PC-3, DuPro and CWR22Rv1) grown in RPMI þ CCS, which is rich in hormones (progesterone, testosterone, cortisol, corticosterone, triiodothyronine and thyroxine), consistently expressed detectable levels of DRa and DRb (Figure 1b, first and second row) . To dissect whether stable class II dimers are present in prostate cancer cells, we focused on two widely used prostate cancer cell lines PC-3 and CWR22Rv1. These two cell lines were grown in RPMI þ CCS, and tested for class II dimer expression. Data clearly showed that PC-3 and CWR22Rv1 cells expressed class II ab dimer (HLA-DR) when cultured in media containing CCS (Figure 1b, third row) . We did not see the presence of stable dimer in DuPro cells under that condition (Figure 1b) , although loading of higher amounts of protein (100 mg) showed a visible band similar to DRb (data not shown). These data suggest Flow cytometry detected HLA-DR and HLA-DR4 molecules on the cell surface
To examine whether prostate cancer cells express mature class II molecules on the cell surface, which would be required for functional antigen presentation, we cultured PC-3 and CWR22Rv1 cells in RPMI þ CCS. Cells were then stained with the HLA-DR-and HLA-DR4-specific antibodies L243 and 359-F10, respectively. Flow cytometric analyses confirmed that PC-3 and CWR22Rv1 express surface HLA-DR molecules when grown in media containing CCS (Figure 2a ). PC-3 and CWR22Rv1 cells transfected with HLA-DR4 (PC-3.DR4 and CWR22Rv1.DR4) expressed high levels of surface DR4 molecules (Figure 2b ). These data confirm that prostate 
T-cell recognition of prostate tumor cells via HLA class II molecules
To investigate whether HLA-DR expressing PC-3 and CWR22Rv1 cells are recognized by CD4 þ T cells, we cocultured these prostate tumor cells with human primary T cells for 48 h followed by quantitation of IFN-g production. Data showed that DR-positive PC-3 and CWR22Rv1 cells cultured in RPMI þ CCS, significantly stimulated human primary T cells (Figure 4 ). These data suggest that these prostate cancer cells express functional class II proteins in CCS-containing media that are recognizable by CD4 þ T cells. The T-cell production of IFN-g was blocked when anti-DR antibody L243 was added to the coculture experiments (Figure 4) , suggesting that the antigen presentation was DRmediated.
We also tested whether genetically manipulated class II-expressing prostate cancer cells present PSMA peptides to stimulate CD4 þ T cells. To test this, PC-3 and CWR22Rv1 cells were transfected with a specific class II allele DRB1*0401 to generate DR4-expressing PC-3.DR4 and CWR22Rv1.DR4 cells. PC-3.DR4 cells were then incubated with either whole PSMA (Figure 5a ) or the PSMA 206À220 peptide (Figure 5b) , followed by coculture with the peptide specific CD4 þ T cells as described. 29, 33 Cell supernatants were analyzed by ELISA for the quantitation of interleukin-2. HLA-DR4-transfected melanoma line J3.DR4 which stimulates CD4 þ T cells, was used as a control. Data clearly showed that PC3.DR4 cells functionally presented the PSMA 206-220 epitope as well as the synthetic PSMA 206À220 peptide to CD4 þ T cells ( Figure 5) . Coculture experiments using untransfected, DR4-negative PC-3 and CWR22Rv1 cells, did not produce any interleukin-2 ( Figure 5) , suggesting that the DR4-mediated delivery of peptides occurred through the HLA class II pathway. To examine whether endogenous PSMA is presented to CD4 þ T cells, we cocultured CWR22Rv1.DR4 cells that innately express PSMA with the A9 cells. Data showed that CWR22Rv1.DR4 cells efficiently stimulated PSMA 206À220 peptide specific CD4 þ T cells (Figure 5c ), suggesting that prostate cancer cells are able to present their own antigens and/or peptides, inducing antitumor immune responses.
Discussion
Successful immunotherapeutic vaccinations require concerted CD8 þ and CD4 þ lymphocyte responses. While considerable knowledge of CD8 þ T-cell responses to tumor antigens has been gained, little is known about the presentation of tumor antigens via the HLA class II pathway. This study was undertaken to critically examine whether prostate tumor cells express functional class II molecules capable of stimulating CD4 þ T cells. This line of research has shown for the first time that prostate tumor cells are capable of endogenously Throughout the course of our examination of multiple prostate cancer cell lines, we have consistently seen endogenous expression of the class II a-and b-subunit when the cells are grown in CCS-containing media. We chose to narrow the focus of our study to two widely used prostate cancer cell lines, PC-3 and CWR22Rv1, culturing these cells in CCS-containing media which contains a number of hormones such as progesterone, testosterone, cortisol, corticosterone, triiodothyronine and thyroxine. We standardized a culture condition that is suitable for class II protein expression by prostate tumor cells. In this culture (cells grown in RPMI þ CCS) condition, we observed increased expression of the a-and b-subunit of the HLA class II molecule and formation of the stable HLA class II dimeric protein, as shown in Figure 1b . This observation raises the possibility that in the appropriate in vivo hormone environment, prostate tumor cells may express class II molecules capable of stimulating CD4 þ T cells through the class II pathway. The hormones present at high concentrations in the enriched CCS used to culture prostate cancer cells might function to activate the CIITA gene that regulates the expression of the HLA class II proteins. Studies suggest that one of the most prominent escape mechanisms of malignant tissues is to avoid immune detection through downregulation of HLA protein expression. 45, 46 This phenomenon was investigated in prostate cancer cell lines and primary prostate tumors. The effects of CCS in the induction of HLA class II expression and in propagating an immune response strongly denote future implications for the effective immunotherapy of prostate cancer.
While prostate cancer cells grown in CCS-containing media expressed steady state class II proteins (Figure 1b) , they also expressed mature class II molecules on the surface (Figure 2) . However, the components of the HLA class II pathway such as Ii and DM were undetected in these cells (Figure 3 ). Even IFN-g-treated prostate tumor cells only minimally expressed Ii but no DM molecules (data not shown). These data suggest that Ii-and DMindependent class II antigen presentation pathways exist in these tumors as demonstrated previously in other malignant cells and non-professional APCs. 47, 48 Ii-negative class II-expressing tumor cells have also been shown to be immunogenic, inducing antitumor immune responses. 49, 50 Thus, Ii-negative/DR þ prostate tumor cells may directly present self-antigens to stimulate CD4 þ T cells. In this study, we were able to demonstrate that HLA class II-bearing prostate tumor cells stimulate primary T cells (Figure 4) . Prostate cancer cells transduced with class II molecules also efficiently presented both exogenous and endogenous tumor antigens to CD4 þ T cells ( Figure 5 ). These data raise the possibility that prostate tumor cells could be converted to an efficient APCs that can present their own antigens initiating strong immune responses as reported in other tumor models. 50, 51 To elicit strong T-cell responses, tumor antigens must be processed by tumors, bystander non-professional APCs, as well as professional APC. The activation of antitumor immune responses further depends on how efficiently the relevant tumor antigen peptides are delivered into the HLA class I/II presentation pathway for T-cell recognition. The findings that prostate cancer cells express functional HLA class II ab dimers will help design a protective vaccine against the tumor by triggering tumor antigen presentation to CD4 þ T cells and establishment of antitumor immune memory. Figure 5 HLA-DR4-restricted tumor antigen presentation and CD4 þ T-cell recognition of human prostate cancer cells. DR4-transfected prostate cancer cells, PC-3.DR4, were incubated with either whole PSMA (a) or PSMA 206À220 peptide (b) for overnight, followed by coculture with the peptide-specific CD4 þ T cells (A9). The melanoma cells J3 or those transfected with DR4, J3.DR4, were used as controls. CWR22Rv1.DR4 cells that innately express PSMA were cocultured with the A9 cells (c). T-cell production of IL-2 was quantitated by ELISA. Data are expressed as mean IL-2 production (pg ml À1 )±s.e.m. of triplicate wells and are representative of three independent experiments. ELISA, enzyme-linked immunosorbent assay; IL-2, interleukin; HLA, human leukocyte antigen; PSMA, prostate-specific membrane antigen.
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